{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:13:51Z","timestamp":1774548831959,"version":"3.50.1"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Despite advances in multimodal treatment, the long-term survival of patients with resectable pancreatic ductal adenocarcinoma (PDAC) remains poor. In Japan, neoadjuvant chemotherapy with gemcitabine and S-1 (GS) has demonstrated a survival benefit compared with upfront surgery. The addition of radiotherapy to chemotherapy may further improve outcomes by enhancing local tumor control and increasing R0 resection rates; however, no randomized trial has directly compared GS alone with GS plus radiotherapy (GS-RT) in patients with resectable PDAC. The CSGO-HBP-027 trial is a multicenter, randomized phase II\/III study designed to evaluate whether neoadjuvant GS-RT improves survival compared with GS alone. This trial will enroll 200 patients with resectable PDAC, who will be randomized in a 1:1 ratio to receive either two cycles of GS or two cycles of GS with concurrent radiotherapy (50.4 Gy in 28 fractions), followed by surgery scheduled 3\u20138 weeks after completion of neoadjuvant therapy. The primary endpoint is overall survival, and secondary endpoints include resection rate, R0 resection rate, histological tumor response, progression-free survival, and safety. Overall survival will be compared between the two treatment arms using the stratified log-rank test, with adjusted hazard ratios estimated using the Cox proportional hazards model. This trial was registered with the Japan Registry of Clinical Trials (jRCTs051250150). The CSGO-HBP-027 trial will provide evidence on whether neoadjuvant GS-RT improves survival in patients with resectable PDAC compared with GS alone. The results of this study are expected to clarify the optimal neoadjuvant treatment strategy for resectable PDAC and to provide high-quality evidence regarding the clinical value of adding radiotherapy to GS-based neoadjuvant therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0345459","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:24:02Z","timestamp":1774545842000},"page":"e0345459","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027)"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-060X","authenticated-orcid":true,"given":"Yoshito","family":"Tomimaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-9466","authenticated-orcid":true,"given":"Hirofumi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-5686","authenticated-orcid":true,"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikato","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-6506","authenticated-orcid":true,"given":"Akira","family":"Tomokuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tsujie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiteru","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-5341","authenticated-orcid":true,"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-1129","authenticated-orcid":true,"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"pone.0345459.ref001","unstructured":"Cancer Statistics in Japan. 2025."},{"issue":"1","key":"pone.0345459.ref002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"RL Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"pone.0345459.ref003","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamasurg.2015.0668","article-title":"Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma","volume":"150","author":"A Paniccia","year":"2015","journal-title":"JAMA Surg"},{"issue":"14","key":"pone.0345459.ref004","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"H Oettle","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"pone.0345459.ref005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II\/III Prep-02\/JSAP05 Trial","volume":"283","author":"M Unno","year":"2026","journal-title":"Ann Surg"},{"issue":"4","key":"pone.0345459.ref006","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","article-title":"Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis","volume":"28","author":"T Okusaka","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"pone.0345459.ref007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/SLA.0b013e3181ad65cc","article-title":"Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer","volume":"250","author":"H Ohigashi","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"pone.0345459.ref008","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","article-title":"Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer","volume":"258","author":"H Takahashi","year":"2013","journal-title":"Ann Surg"},{"issue":"16","key":"pone.0345459.ref009","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"E Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0345459.ref010","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"E Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"pone.0345459.ref011","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","article-title":"A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma","volume":"26","author":"H Eguchi","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"pone.0345459.ref012","unstructured":"National Comprehensive Cancer Network NCCN. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. 2025."},{"issue":"2","key":"pone.0345459.ref013","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"7","key":"pone.0345459.ref014","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","article-title":"Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)","volume":"31","author":"D Yamada","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"pone.0345459.ref015","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"11","key":"pone.0345459.ref016","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"127","author":"DB Evans","year":"1992","journal-title":"Arch Surg"},{"key":"pone.0345459.ref017","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial","volume":"34","author":"B Groot Koerkamp","year":"2023","journal-title":"Annals of Oncology"},{"issue":"11","key":"pone.0345459.ref018","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"T Sugiura","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"pone.0345459.ref019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4014","article-title":"Randomized phase II\/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study","volume":"42","author":"M Ikeda","year":"2024","journal-title":"JCO"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:24:12Z","timestamp":1774545852000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345459"}},"subtitle":[],"editor":[{"given":"Aimin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345459","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}